Sponsors (4)
The bill increases detection, monitoring, and treatment linkage for tardive dyskinesia—improving patient health outcomes—while likely raising healthcare costs and risking greater anxiety or stigma among medication users.
People taking antipsychotic or antiemetic medications are more likely to be diagnosed earlier and connected to FDA‑approved treatments for tardive dyskinesia because the bill promotes awareness and screening.
Patients on antipsychotics/antiemetics will receive more regular TD monitoring by clinicians, reducing the duration of untreated symptoms and the associated physical, social, and emotional harms.
Broader public and medical‑community awareness is likely to improve detection rates and linkage to care for people with TD, increasing the likelihood they get appropriate follow-up and services.
Patients and payers (including taxpayers) may face higher healthcare costs if uptake of expanded screening and therapies increases.
People taking antipsychotics or antiemetics may experience increased anxiety or stigma as a result of heightened awareness campaigns about TD risk.
Based on analysis of 1 section of legislative text.
Affirms findings on tardive dyskinesia, urges greater awareness and regular screening, and notes FDA-approved treatments exist for adults.
Official title: Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week".
Introduced May 7, 2026 by Scott Peters · Last progress May 7, 2026
Declares findings about tardive dyskinesia (TD), a sometimes underdiagnosed involuntary movement disorder linked to prolonged use of certain antipsychotic and antiemetic medicines, and encourages greater awareness, regular screening, and recognition that FDA-approved treatments exist for adults. It highlights that TD affects an estimated 600,000 people in the U.S., with many cases undiagnosed, and stresses that even mild symptoms can cause physical, social, and emotional harm. The text urges the medical community and public to increase detection and monitoring practices consistent with clinical guidance so that people with TD can be identified and offered appropriate treatment, though it does not create new programs or funding.